NASDAQ:HTGM HTG Molecular Diagnostics - HTGM Stock Forecast, Price & News Notice: This company has been marked as potentially delisted and may not be actively trading. Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding HTG Molecular Diagnostics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Add Compare Share Share Today's Range$3.50▼$3.6950-Day Range$5.01▼$6.8052-Week Range$3.50▼$7.95Volume66,714 shsAverage Volume107,006 shsMarket Capitalization$3.39 millionP/E RatioN/ADividend YieldN/APrice Target$2.83 ProfileAnalyst RatingsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media HTG Molecular Diagnostics MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside23.2% Downside$2.83 Price TargetShort InterestHealthy6.58% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.00Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($20.32) to ($3.61) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.22 out of 5 stars 1.5 Analyst's Opinion Consensus RatingHTG Molecular Diagnostics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $2.83, HTG Molecular Diagnostics has a forecasted downside of 23.2% from its current price of $3.69.Amount of Analyst CoverageHTG Molecular Diagnostics has received no research coverage in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted6.58% of the float of HTG Molecular Diagnostics has been sold short.Short Interest Ratio / Days to CoverHTG Molecular Diagnostics has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in HTG Molecular Diagnostics has recently decreased by 55.81%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldHTG Molecular Diagnostics does not currently pay a dividend.Dividend GrowthHTG Molecular Diagnostics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for HTGM. Previous Next 0.0 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 3 news articles for HTG Molecular Diagnostics this week, compared to 1 article on an average week.MarketBeat FollowsOnly 1 people have added HTG Molecular Diagnostics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, HTG Molecular Diagnostics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.60% of the stock of HTG Molecular Diagnostics is held by insiders.Percentage Held by InstitutionsOnly 19.27% of the stock of HTG Molecular Diagnostics is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for HTG Molecular Diagnostics are expected to grow in the coming year, from ($20.32) to ($3.61) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of HTG Molecular Diagnostics is -0.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of HTG Molecular Diagnostics is -0.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioHTG Molecular Diagnostics has a P/B Ratio of 0.22. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About HTG Molecular Diagnostics (NASDAQ:HTGM) StockHTG Molecular Diagnostics, Inc. engages in the provision of molecular technology solutions that facilitates molecular profiling. It serves the biopharmaceutical companies, academic research centres, and molecular testing laboratories. Its proprietary HTG EdgeSeq technology automates complex, highly multiplexed molecular profiling from solid and liquid samples, even when limited in amount. The company was founded by Bruce E. Seligmann in October 1997 and is headquartered in Tucson, AZ.Read More Receive HTGM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for HTG Molecular Diagnostics and its competitors with MarketBeat's FREE daily newsletter. Email Address HTGM Stock News HeadlinesMarch 24, 2023 | msn.comWhy Heron Therapeutics Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving PremarketJanuary 25, 2023 | seekingalpha.comHTGM HTG Molecular Diagnostics, Inc.March 29, 2023 | Investor Place Media (Ad)Biden To Unleash "Choke Point" Operation On America?Biden's disturbing new government program may be worse than Obama's. You are at risk for having your bank account frozen. A former bank regulator is blowing the whistle on Biden's frightening plan to take over your money. Discover the immediate steps you need to take now.January 9, 2023 | finance.yahoo.comHTG Provides a Year-End Update on its Drug Discovery Business and Attends LifeSci Partners 2023 Corporate Access EventJanuary 6, 2023 | msn.comHTG Molecular Diagnostics expects FY22 revenue above consensusJanuary 6, 2023 | ca.finance.yahoo.comHTG Announces Certain Preliminary 2022 Unaudited Financial ResultsJanuary 6, 2023 | finance.yahoo.comHTG Announces Certain Preliminary 2022 Unaudited Financial ResultsDecember 30, 2022 | bizjournals.comHTG Molecular Diagnostics of Tucson raises $10M in public offeringMarch 29, 2023 | Behind the Markets (Ad)Buy THIS stock before Taiwan is attacked... If the United States goes to war with another nuclear armed superpower, this could have a devastating impact on your retirement portfolio. Now, even Taiwan's own foreign minister is saying that China is on the cusp of a full scale invasion. But the good news is, if China invades Taiwan, there is a way to protect yourself.December 29, 2022 | msn.comPeering Into HTG Molecular Diagnostics's Recent Short InterestDecember 28, 2022 | finance.yahoo.comHTG Molecular Diagnostics Provides Highlights of its Second Event in Drug Discovery KOL Webcast SeriesDecember 27, 2022 | msn.comWhat Does HTG Molecular Diagnostics' Debt Look Like?December 27, 2022 | benzinga.comWhy HTG Molecular Diagnostics (HTGM) Stock Is Popping Off TodayDecember 24, 2022 | finanznachrichten.deHTG Molecular Diagnostics, Inc.: HTG Molecular Diagnostics Announces Closing of a $10 Million Public OfferingDecember 23, 2022 | finance.yahoo.comHTG Molecular Diagnostics Announces Closing of a $10 Million Public OfferingDecember 22, 2022 | finanznachrichten.deHTG Molecular Diagnostics, Inc.: HTG Molecular Diagnostics Announces Pricing of a $10 Million Public OfferingDecember 21, 2022 | msn.comHTG Molecular stock dips after pricing $10M securities offeringDecember 21, 2022 | finance.yahoo.comHTG Molecular Diagnostics Announces Pricing of a $10 Million Public OfferingDecember 21, 2022 | msn.comWhat Is Going on With HTG Molecular Diagnostics (HTGM) Stock Today?December 21, 2022 | finanznachrichten.deHTG Molecular Diagnostics, Inc.: HTG Announces One-for-Twelve Reverse Stock SplitDecember 20, 2022 | finance.yahoo.comHTG Announces One-for-Twelve Reverse Stock SplitDecember 13, 2022 | msn.comLooking Into HTG Molecular Diagnostics's Recent Short InterestDecember 12, 2022 | msn.comHTG Molecular Diagnostics' Debt OverviewDecember 12, 2022 | benzinga.comWhy Harpoon Therapeutics Shares Are Trading Higher By 97%? Here Are 53 Stocks Moving In Monday's Mid-Day SessionDecember 9, 2022 | finance.yahoo.comHTG Molecular Diagnostics Announces the Next Event in its RNA Profiling in Drug Discovery KOL Webcast SeriesDecember 6, 2022 | finance.yahoo.comHTG Technology Featured Across Numerous Abstracts at Upcoming Scientific ConferencesNovember 11, 2022 | markets.businessinsider.comH.C. Wainwright Reaffirms Their Buy Rating on HTG Molecular Diagnostics (HTGM)See More Headlines Receive HTGM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for HTG Molecular Diagnostics and its competitors with MarketBeat's FREE daily newsletter. Email Address HTGM Company Calendar Last Earnings11/10/2021Today3/28/2023Next Earnings (Estimated)4/04/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Analytical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:HTGM CUSIPN/A CIK1169987 Webwww.htgmolecular.com Phone(520) 547-2827Fax520-547-2837Employees84Year FoundedN/APrice Target and Rating Average Stock Price Forecast$2.83 High Stock Price Forecast$3.50 Low Stock Price Forecast$2.00 Forecasted Upside/Downside-23.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($29.4118) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-17,150,000.00 Net Margins-324.66% Pretax Margin-324.53% Return on Equity-310.67% Return on Assets-93.28% Debt Debt-to-Equity Ratio1.08 Current Ratio1.58 Quick Ratio1.33 Sales & Book Value Annual Sales$8.91 million Price / Sales0.38 Cash FlowN/A Price / Cash FlowN/A Book Value$16.45 per share Price / Book0.22Miscellaneous Outstanding Shares920,000Free Float896,000Market Cap$3.39 million OptionableOptionable Beta1.05 Key ExecutivesJohn L. LubniewskiPresident, Chief Executive Officer & DirectorShaun D. McMeansCFO, Secretary, Treasurer & SVP-AdministrationByron T. LawsonChief Commercial Officer & Senior Vice PresidentLaura L. GodlewskiChief Accounting Officer & Vice President-FinanceSam M. RuaSenior VP-Regulatory Affairs & Quality SystemsKey CompetitorsSeqLLNASDAQ:SQLFirst Wave BioPharmaNASDAQ:FWBIBIMI International MedicalNASDAQ:BIMIBellicum PharmaceuticalsNASDAQ:BLCMMotus GINASDAQ:MOTSView All Competitors HTGM Stock - Frequently Asked Questions Should I buy or sell HTG Molecular Diagnostics stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for HTG Molecular Diagnostics in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" HTGM shares. View HTGM analyst ratings or view top-rated stocks. What is HTG Molecular Diagnostics' stock price forecast for 2023? 3 Wall Street analysts have issued 1-year price objectives for HTG Molecular Diagnostics' shares. Their HTGM share price forecasts range from $2.00 to $3.50. On average, they predict the company's stock price to reach $2.83 in the next twelve months. This suggests that the stock has a possible downside of 23.2%. View analysts price targets for HTGM or view top-rated stocks among Wall Street analysts. Are investors shorting HTG Molecular Diagnostics? HTG Molecular Diagnostics saw a decline in short interest in the month of March. As of March 15th, there was short interest totaling 48,300 shares, a decline of 55.8% from the February 28th total of 109,300 shares. Based on an average daily volume of 1,290,000 shares, the short-interest ratio is presently 0.0 days. Approximately 6.6% of the shares of the stock are short sold. View HTG Molecular Diagnostics' Short Interest. When is HTG Molecular Diagnostics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, April 4th 2023. View our HTGM earnings forecast. How were HTG Molecular Diagnostics' earnings last quarter? HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) announced its earnings results on Wednesday, November, 10th. The medical research company reported ($0.60) earnings per share for the quarter, hitting the consensus estimate of ($0.60). The medical research company had revenue of $2.52 million for the quarter, compared to the consensus estimate of $2.90 million. HTG Molecular Diagnostics had a negative trailing twelve-month return on equity of 310.67% and a negative net margin of 324.66%. During the same period in the previous year, the company posted ($1.05) earnings per share. What guidance has HTG Molecular Diagnostics issued on next quarter's earnings? HTG Molecular Diagnostics issued an update on its FY 2022 earnings guidance on Friday, January, 6th. The company provided EPS guidance of for the period. The company issued revenue guidance of $6.40 million-$6.40 million, compared to the consensus revenue estimate of $5.70 million. What is Tim (TJ) Johnson's approval rating as HTG Molecular Diagnostics' CEO? 11 employees have rated HTG Molecular Diagnostics Chief Executive Officer Tim (TJ) Johnson on Glassdoor.com. Tim (TJ) Johnson has an approval rating of 47% among the company's employees. This puts Tim (TJ) Johnson in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of HTG Molecular Diagnostics own? Based on aggregate information from My MarketBeat watchlists, some companies that other HTG Molecular Diagnostics investors own include Idera Pharmaceuticals (IDRA), Biocept (BIOC), Rigel Pharmaceuticals (RIGL), Heat Biologics (HTBX), MEI Pharma (MEIP), Zosano Pharma (ZSAN), Verastem (VSTM), Aurinia Pharmaceuticals (AUPH), Dynavax Technologies (DVAX) and Gilead Sciences (GILD). When did HTG Molecular Diagnostics IPO? (HTGM) raised $50 million in an initial public offering on Wednesday, May 6th 2015. The company issued 3,600,000 shares at a price of $13.00-$15.00 per share. Leerink Partners acted as the underwriter for the IPO and Canaccord Genuity and JMP Securities were co-managers. What is HTG Molecular Diagnostics' stock symbol? HTG Molecular Diagnostics trades on the NASDAQ under the ticker symbol "HTGM." Who are HTG Molecular Diagnostics' major shareholders? HTG Molecular Diagnostics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Concourse Financial Group Securities Inc. (0.00%). View institutional ownership trends. What is HTG Molecular Diagnostics' stock price today? One share of HTGM stock can currently be purchased for approximately $3.69. How much money does HTG Molecular Diagnostics make? HTG Molecular Diagnostics (NASDAQ:HTGM) has a market capitalization of $3.39 million and generates $8.91 million in revenue each year. The medical research company earns $-17,150,000.00 in net income (profit) each year or ($29.4118) on an earnings per share basis. How can I contact HTG Molecular Diagnostics? HTG Molecular Diagnostics' mailing address is 3430 E. GLOBAL LOOP, TUCSON AZ, 85706. The official website for the company is www.htgmolecular.com. The medical research company can be reached via phone at (520) 547-2827, via email at arr@lifesciadvisors.com, or via fax at 520-547-2837. This page (NASDAQ:HTGM) was last updated on 3/29/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.